CS
LAB icon

Candriam SCA’s Standard BioTools LAB Stock Holding History

Candriam SCA’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-173,646
Closed -$1.07M – 892
2021
Q2 		$1.07M Sell
173,646
-144,685
-45% -$773K 0.01% 708
2021
Q1 		$1.83M Hold
318,331
– – 0.02% 533
2020
Q4 		$1.91M Buy
318,331
+33,331
+12% +$219K 0.02% 545
2020
Q3 		$2.12M Buy
+285,000
New +$1.97M 0.02% 496
2016
Q1 		– Sell
-79,000
Closed -$854K – 645
2015
Q4 		$854K Buy
79,000
+22,000
+39% +$216K 0.02% 405
2015
Q3 		$462K Buy
+57,000
New +$897K 0.01% 540

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Candriam SCA's LAB Position: Q3 2021 in Review

Candriam SCA sold out of Standard BioTools (LAB) in Q3 2021, closing a stake of 173,646 shares — an estimated $1.07M sold.

Candriam SCA first reported a position in LAB in Q3 2015 and held it in 6 quarters. The position peaked at $2.12M in Q3 2020. 119 funds tracked by Wall St. Rank hold LAB as of Q3 2021.

  • Candriam SCA reported no remaining Standard BioTools position as of Q3 2021 after selling out during the quarter.
  • Candriam SCA sold 173,646 Standard BioTools shares in Q3 2021, an estimated $1.07M.
  • Candriam SCA first reported a position in Standard BioTools in Q3 2015 and held it in 6 quarters.
  • Candriam SCA's Standard BioTools position peaked at $2.12M in Q3 2020.
  • 119 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2021.

Based on Candriam SCA's 13F filing for Q3 2021, filed 9 Nov 2021.